Levels predict lung cancer (NSCLC) recurrence and survival.

EphA2 expression in non small cell lung carcinoma is associated with K-Ras mutations, EGFR activation, smoking history, and poor prognosis.

Overexpression of the receptor tyrosine kinase EphA2 is associated with non-small cell lung cancer.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation

A critical role for JNK signaling in EPHA2-dependent lung cancer cell proliferation and motility.

Role for EPHA2 in the maintenance of cell survival of TKI-resistant, EGFR-mutant lung cancer and indicate that EPHA2 may serve as a useful therapeutic target in TKI-resistant tumors.

cells with Lipoplatin. The combined effects of siRNA-EphA2 and Lipoplatin were determined. We report that silencing EphA2 significantly enhanced the cellular sensitivity of lung tumor and MPM cells to Lipoplatin and maybe a potential therapy for lung cancer.